Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03PSP
|
|||
| Former ID |
DIB015066
|
|||
| Drug Name |
Panobacumab
|
|||
| Synonyms |
KBPA-101; Human monoclonal antibody (Pseudomonas aeruginosa), Berna; MAb (Pseudomonas aeruginosa), Berna
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Hospital-acquired pneumonia [ICD-11: CA40.Z] | Phase 2 | [1] | |
| Ventilator-associated pneumonia [ICD-11: PK81.0] | Phase 2 | [1] | ||
| Pseudomonas infection [ICD-11: 1B92; ICD-10: A24, A24.0] | Phase 1/2 | [1] | ||
| Company |
Aridis Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Pseudomonas Lipopolysaccharide (Pseudo LPS) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00851435) Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa. U.S. National Institutes of Health. | |||
| REF 2 | Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.